Inventor
GIOVANNI COPPOLA
Inventor
US
Overview
Patents· 10 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Qprimary
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms24%
A61KPreparations for medical, dental or toiletry purposes21%
C12NMicroorganisms or enzymes19%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations17%
C07KPeptides10%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds2%
PatentTitleYear
12,577,562Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors202612,370,257Materials and methods of treating MHC-I-opathy risk haplotypes202512,258,627Kelch domain containing 7B (KLHDC7B) variants and uses thereof202512,157,891Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors202411,865,134Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors202411,845,989Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors202311,820,982Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors202311,767,526Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors202311,674,177Kelch domain containing 7B (KLHDC7B) variants and uses thereof202311,512,309Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to REGENERON PHARMA (10)· patent assignee history
2022–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 10 | 2022–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 10 | 2022–2026 |